Immunome (IMNM) Current Assets (2019 - 2026)
Immunome's (IMNM) quarterly Current Assets came in at $594.3 million in Q1 2026, up 83.92% YoY from $323.1 million in Q1 2025, and down 10.06% on a QoQ basis from $660.8 million in Q4 2025.
Immunome (IMNM) Current Assets (2019 - 2026) Analysis & Trends
Immunome (IMNM) has 8 years of Current Assets data on file, last reported at $594.3 million in Q1 2026.
- Quarterly Current Assets rose 83.92% year-over-year to $594.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $594.3 million (up 83.92% YoY) and the FY2025 annual result came in at $660.8 million, up 198.54% from the prior year.
- Current Assets retreated to $594.3 million in Q1 2026, from $660.8 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $660.8 million in Q4 2025 to a low of $22.6 million in Q4 2022.
- A 5-year average of $215.1 million and a median of $221.3 million in 2024 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2022 — Current Assets sank 60.01% — and 2024, when it surged 619.23%.
- Tracing IMNM's Current Assets over 5 years: stood at $22.6 million in 2022, then soared by 538.89% to $144.7 million in 2023, then soared by 52.96% to $221.3 million in 2024, then jumped by 198.54% to $660.8 million in 2025, then decreased by 10.06% to $594.3 million in 2026.
- The last three Current Assets figures came in at $594.3 million (Q1 2026), $660.8 million (Q4 2025), and $279.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Immunome | 3.09 Bn | 2.57 Bn | - | 538.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 538.45 Mn |
| Mar 31, 2026 | 594.31 Mn |
| Dec 31, 2025 | 660.78 Mn |
| Sep 30, 2025 | 279.92 Mn |
| Jun 30, 2025 | 277.43 Mn |
| Mar 31, 2025 | 323.13 Mn |
| Dec 31, 2024 | 221.34 Mn |
| Sep 30, 2024 | 244.04 Mn |
| Jun 30, 2024 | 284.28 Mn |
| Mar 31, 2024 | 313.33 Mn |
| Dec 31, 2023 | 144.70 Mn |
| Sep 30, 2023 | 91.41 Mn |
| Jun 30, 2023 | 39.53 Mn |
| Mar 31, 2023 | 46.54 Mn |
| Dec 31, 2022 | 22.65 Mn |
| Sep 30, 2022 | 29.24 Mn |
| Jun 30, 2022 | 37.60 Mn |
| Mar 31, 2022 | 46.30 Mn |
| Dec 31, 2021 | 56.64 Mn |
| Sep 30, 2021 | 61.19 Mn |